Pfizer’s Quarterly Results Beat Expectations on Cancer, Heart Drugs

Pfizer reported better-than-expected second-quarter results, arsenic rising income of drugs for crab and bosom illness helped offset steep declines for Covid-19 products.

The New York institution besides somewhat raised the bottommost extremity of its forecast scope for full-year 2026 revenue.

Most Read from The Wall Street Journal

• The AI Boom Is Transforming the American Economy Beyond Recognition

• Whirlpool Abandoned Its Global Ambitions. Now It's successful a World of Hurt.

• Anduril Weighs Baltimore Shipyard Investment to Build Drone Boats

• Why Bessent Is Leaning connected the Fed to Help Prop Up Japan's Currency

• Zach Dell Is Raising Money to Put a Battery successful Your Backyard

Pfizer shares were mostly unchanged successful premarket trading.

Pfizer is trying to retrieve from a postpandemic hangover successful which request for its Covid-19 vaccine and attraction person plummeted. It is bracing for patent expirations connected starring drugs that volition unit its gross maturation successful coming years, and the institution said Tuesday it is expanding ongoing cost-cutting programs.

The institution is processing caller medicines and has made acquisitions—including a large stake connected weight-loss drugs—aimed astatine returning to coagulated growth, but it could instrumentality immoderate clip to spot if those wage off.

As portion of its strategy to beef up its pipeline, Pfizer agreed to get weight-loss cause startup Metsera past twelvemonth successful a woody that could beryllium valued astatine much than $10 billion.

Pfizer said Tuesday it recorded a second-quarter nonaccomplishment of $248 million, oregon 4 cents a share, compared with a nett of $2.91 billion, oregon 51 cents a share, a twelvemonth earlier.

The nonaccomplishment was mostly owed to a $3.8 cardinal complaint to constitute down the worth of an experimental cause aft a survey showed it didn't importantly prolong endurance successful lung-cancer patients. Pfizer had acquired the cause successful its $43 cardinal acquisition of Seagen successful 2023.

Stripping retired that write-down and definite one-time items, adjusted per-share net were 77 cents, up of the 68 cents anticipated by analysts, according to FactSet.

Revenue roseate 3% to $15.03 billion, topping the $14.40 cardinal mean estimation of analysts surveyed by FactSet.

Sales were driven by 2% maturation successful Pfizer's biopharma concern and 7% maturation successful Pfizer CentreOne, the company's declaration improvement and manufacturing organization.

The humor thinner Eliquis and heart-disease attraction Vyndaqel helped substance gross growth. Cancer treatments Padcev and Lorbrena some gained marketplace stock and posted higher sales.

Paxlovid and Comirnaty, 2 of its Covid products, saw income driblet 95% and 34%, respectively. The declines were driven by little Covid infections and a narrower proposal for who should get Covid shots.